Mustang Bio (MBIO) AI Stock Analysis

• Market Cap: $5.12M
• Dividend Yield: N/A
• Average Volume (3M): 102.20K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.22
• Revenue Growth: N/A
• EPS Growth: 85.97%
• Country: US
• Employees: 6
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): -43.66
• Shares Outstanding: 3,532,452
• 10 Day Avg. Volume: 57,832
• 30 Day Avg. Volume: 102,202
• PEG Ratio: -5.66
• Price to Book (P/B): 44.14
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -29.97
• Enterprise Value/Market Cap: 390.08
• Enterprise Value/Revenue: 346.64
• Enterprise Value/Gross Profit: -6.66K
• Enterprise Value/Ebitda: -25.69
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 31 Underperform
• Price Target: ―

Mustang Bio's overall stock performance is hindered by significant financial instability, including zero revenues and continuous losses. While technical indicators suggest bearish momentum, the recent asset sale to AbbVie provides a glimmer of hope for cost reduction. However, the lack of earnings call data limits insights into future guidance, further emphasizing the need for caution.

Mustang Bio Business Overview & Revenue Model

Company Description

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

How the Company Makes Money

Mustang Bio generates revenue primarily through strategic partnerships, licensing agreements, and collaborations with other biopharmaceutical companies and research institutions. These partnerships may involve upfront payments, milestone payments, and royalties based on the successful development and commercialization of their therapies. Additionally, Mustang Bio may also receive funding from grants or government contracts aimed at supporting innovative research and development in the field of gene and cell therapies. The company is focused on advancing its clinical trials to bring its products to market, which will eventually result in direct sales revenue from approved therapies.

Mustang Bio Financial Statement Overview

Summary

Mustang Bio faces significant financial challenges, including zero revenue, heavy losses, negative equity, and reliance on external financing. These factors highlight precarious financial health and the need for strategic initiatives to stabilize operations.

Income Statement

Mustang Bio has consistently reported zero revenue over the years, indicating no income generation from operations. The company's EBIT and net income are both negative, reflecting significant operational losses. The lack of revenue growth and continuous losses highlight potential challenges in achieving profitability.

Balance Sheet

The company's balance sheet reveals a negative stockholders' equity in the latest period, signaling financial instability. The debt-to-equity ratio cannot be calculated accurately due to negative equity. These factors point to high financial leverage and potential risks associated with insolvency.

Cash Flow

Mustang Bio's cash flows indicate negative operating cash flow and free cash flow, reflecting cash outflows from operations without revenue support. The company's reliance on financing activities to sustain operations poses a risk to long-term liquidity if external funding is not maintained.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-300.00K	0.00	-2.23M	-3.03M	-2.31M	-1.78M
	EBIT
-11.27M	-16.25M	-50.73M	-76.16M	-66.72M	-56.81M
	EBITDA
-10.61M	-16.25M	-48.06M	-71.14M	-64.05M	-54.31M
	Net Income Common Stockholders
-10.71M	-15.75M	-51.60M	-78.89M	-64.08M	-62.15M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
14.23M	6.84M	6.23M	75.66M	109.62M	97.80M
	Total Assets
14.91M	9.31M	17.74M	92.42M	125.17M	109.90M
	Total Debt
0.00	878.00K	2.50M	31.38M	2.03M	2.23M
	Net Debt
-14.23M	-5.96M	-3.74M	-44.27M	-107.58M	-95.58M
	Total Liabilities
11.30M	13.18M	17.62M	46.15M	12.77M	11.46M
	Stockholders Equity
3.61M	-3.87M	123.00K	46.27M	112.40M	98.44M
Cash Flow		Free Cash Flow
-7.48M	-11.41M	-49.59M	-68.14M	-59.03M	-41.73M
	Operating Cash Flow
-7.48M	-11.41M	-49.48M	-65.07M	-53.67M	-37.32M
	Investing Cash Flow
1.17M	0.00	5.89M	-2.95M	-5.37M	-4.41M
	Financing Cash Flow
18.83M	11.27M	-26.08M	34.06M	70.85M	78.12M

Mustang Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.17
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MBIO, the sentiment is Negative. The current price of 1.17 is below the 20-day moving average (MA) of 1.26, below the 50-day MA of 1.24, and below the 200-day MA of 6.56, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.25 is Neutral, neither overbought nor oversold. The STOCH value of 43.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MBIO.

Mustang Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.37B	3.26	-45.10%	3.30%	16.81%	0.02%
MBIO	31 Underperform	$5.12M	―	270.52%	―	―	85.97%
WINT	28 Underperform	$2.17M	―	-120.01%	―	―	97.84%
ATNF		$5.61M	―	-221.23%	―	―	―
AEON	24 Underperform	$10.30M	<0.01	13.29%	―	―	-261.69%
ALZN		$2.60M	―	-1092.96%	―	―	―
DRMA	15 Underperform	$4.54M	―	-206.26%	―	―	75.68%

Mustang Bio Corporate Events

Mustang Bio Sells Assets to AbbVie, Transfers Lease

Mustang Bio has entered into a Bill of Sale and Surrender Agreement with AbbVie Bioresearch Center Inc., effective from January 31, 2025. As part of this agreement, Mustang Bio will sell certain furniture, fixtures, and equipment located at their Worcester premises to AbbVie for $1.0 million, and AbbVie will take over the lease of the premises. This transaction is expected to potentially save Mustang Bio approximately $2.0 million in lease-related expenses.